Otonomy Initiates Phase 1 Clinical Trial for Tinnitus Product Candidate, OTO-311

Back to Jobs

SAN DIEGO , Nov. 16, 2015 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced the enrollment of the first subjects in a Phase 1

Apply Now